YF454A, a new compound targeting HDACs, has also been reported to inhibit the growth of EGFR-TKI-resistant NSCLC in synergy with erlotinib by blocking cell cycle pathways and the receptor tyrosine kinase pathway7. This evidence concerns the gene EGFR and non-small cell lung carcinoma.